Covid-19 roundup: J&J to ap­ply for boost­er au­tho­riza­tion this week as ad­comms are set; BioN­Tech CEO Ugur Sahin pre­dicts need for new vac­cine for­mu­la­tion

Two weeks af­ter re­leas­ing new da­ta show­ing its Covid-19 boost­er shot bumped pro­tec­tion against mod­er­ate to se­vere dis­ease up to 75% world­wide, J&J is re­port­ed­ly prepar­ing an ap­pli­ca­tion for the FDA.

The phar­ma is plan­ning on ask­ing US reg­u­la­tors ear­ly this week to au­tho­rize its Covid-19 boost­er shot, un­named sources told the New York Times. 

The FDA au­tho­rized Pfiz­er and BioN­Tech’s boost­er shot last month, and is re­port­ed­ly con­sid­er­ing a half-dose boost­er of Mod­er­na’s vac­cine. The agency put out word Fri­day that its Vac­cines and Re­lat­ed Bi­o­log­i­cal Prod­ucts Ad­vi­so­ry Com­mit­tee will meet on Oct. 14 and 15 to dis­cuss Mod­er­na and J&J’s boost­ers, re­spec­tive­ly.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN